Ovarian Cancer

Dr. Jubilee Brown discussed the use of telemedicine and oral treatment options for patients with ovarian cancer, as well as offered advice to ease stress and anxiety throughout the COVID-19 pandemic.

The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.

The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.

The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.

The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.

Treatment with Lynparza in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin.

Understanding ovarian cancer.

The Food and Drug Administration has approved the use of Zejula as a frontline maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who responded to chemotherapy.

A two-time survivor shares how taking action led her doctors to catch an aggressive second cancer.

After failing to meet its primary endpoint of progression-free survival, the JAVELIN Ovarian PARP 100 clinical trial was stopped.

CURE®’s Editor-in-Chief weighs in on how the treatment and detection landscape needs to be refined to help patients with ovarian cancer.

An expert raises her concerns about direct-to-consumer testing and shares ways people can protect themselves.

Regardless of breastfeeding duration, women who did so after giving birth had a lower risk of developing ovarian cancer, including high-grade tumors.

Women with ovarian cancer are living longer than ever, even those whose disease returns after initial treatment.

PARP inhibitors show promise in lengthening the life of women with breast cancer, and they're willing to bear the side effects of the treatment.

These targeted therapies fight disease by stopping the fix-it process in damaged cancer cells.

PARP Inhibitors are opening new doors in cancer treatment by targeting vulnerabilities in cancer that researchers are beginning to understand better.

PARP inhibitors interfere with cancer’s ability to repair damage to its DNA. They are becoming increasingly useful in treating ovarian cancer.

Investigators are studying a rare ovarian tumor called sclerosing stromal tumor, a benign tumor that can be misdiagnosed as cancer.

Take a look back at the top five CURE® stories for January 2020.

From NFL Hall of Famer Kurt Warner leading a recognition service for cancer caregivers during the Super Bowl to Tylenol’s key ingredient possibly being added to California’s proposition 65 list for chemicals that may cause cancer, here’s what is making headlines in the cancer space this week.

One cancer survivor details how her immunotherapy changed her cancer journey for the better, and how ongoing trials of immunotherapy are looking to change the cancer landscape for the better.

Patients with cancer are acutely aware of how time is finite, and that's ok. They can appreciate the fit of time all the better.

In a new study, researchers set out to prove whether or not there was a statistically significant risk of ovarian cancer from the use of talc-based powder.

One cancer survivor discusses the need to talk to others during and after her treatment, and the healing ability of listening as well.

One woman reflects on the fact that no one is immortal.

Launched in April 2018, the podcast hosted by Eleanor Griffith of Grey Genetics tells the stories of people living with genetic mutations that predispose them to cancer or other diseases.